InspireMD is a medical device company headquartered in Tel Aviv, Israel, specializing in the development and commercialization of its proprietary MicroNet stent platform technology for treating vascular and coronary diseases. The company offers products such as the CGuard carotid embolic prevention system, designed for carotid artery applications, and the MGuard Prime embolic protection system, intended for patients with acute coronary syndromes. InspireMD is also working on the NGuard neurovascular flow diverter, which aims to divert blood flow away from cerebral aneurysms. The company generates most of its revenue from the sales of the CGuard system, which integrates MicroNet technology with a self-expandable nitinol stent. Its products are distributed through local partners in various regions, including Europe, Latin America, the Middle East, and Asia.
RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that utilize radioisotopes, particularly focusing on alpha-emitting isotopes like Actinium-225 for the treatment of solid tumors. RayzeBio aims to improve cancer treatment outcomes by creating a robust pipeline of radiopharmaceuticals targeting validated oncology drug targets. Its portfolio includes multiple drug candidates at various stages of development, ranging from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.
Celcuity Inc. is a clinical-stage biotechnology company based in Minneapolis, Minnesota, focused on advancing cancer care through innovative diagnostic and therapeutic solutions. The company's CELsignia diagnostic platform analyzes living tumor cells from patients to identify the specific abnormal cellular processes driving their cancer, enabling personalized treatment options. Celcuity is developing the CELsignia HSF test to diagnose new sub-types of HER2-negative breast cancer, as well as the CELsignia MP test to identify multiple cancer sub-types across various types, including breast, lung, colon, ovarian, kidney, and bladder cancers. In addition to its diagnostic efforts, Celcuity is advancing a lead therapeutic candidate, gedatolisib, a potent pan-PI3K and mTOR inhibitor, which is currently being evaluated in a Phase 3 clinical trial for patients with HR+/HER2- advanced breast cancer. Founded in 2011, Celcuity aims to transform the treatment landscape for patients with cancer by providing targeted therapies tailored to their unique disease profiles.
LimFlow is a developer of innovative peripheral endovascular technology aimed at treating end-stage chronic limb ischemia (CLI) patients. The LimFlow System uses a novel, ultrasound-guided percutaneous procedure to divert blood around diseased arteries into the tibial vein, effectively supplying oxygenated blood to the ischemic foot. This approach offers new hope to patients who have exhausted other revascularization options. By restoring blood flow, the system alleviates ischemic pain, promotes wound healing, reduces the risk of amputations, and helps restore mobility. Currently, the LimFlow System is approved for sale in markets regulated by the CE Mark, while in the United States, it remains an investigational device limited to research use.
Beta Bionics is a biotechnology company based in Boston, Massachusetts, focused on advancing diabetes care through its innovative bionic pancreas system, known as the iLet. Founded in 2015, the company has developed a dual-chamber infusion pump that precisely delivers insulin and glucagon, allowing for autonomous management of blood sugar levels. The iLet has received breakthrough designation for its various configurations, including insulin-only, glucagon-only, and bihormonal uses, particularly in conjunction with Zealand Pharma’s dasiglucagon, a stable glucagon analog in a ready-to-use solution. By reducing the burden and cost associated with diabetes management, Beta Bionics aims to improve the quality of life for individuals living with diabetes.
Parse Biosciences, based in Seattle, Washington, focuses on single-cell analysis and was incorporated in 2018. The company is dedicated to developing innovative technologies that enhance the understanding of cellular diversity and function at the single-cell level. By leveraging advanced methodologies, Parse Biosciences aims to provide researchers with powerful tools for exploring complex biological systems, ultimately advancing the fields of genomics and biomedical research.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, founded in 2018. The company focuses on developing innovative therapies for viral diseases, particularly through its oral drug candidate, ATI-2173, aimed at treating patients infected with Hepatitis B and Hepatitis D viruses. With a leadership team that possesses extensive experience in the field, Antios Therapeutics is dedicated to advancing its research and development efforts toward potentially curative treatments for Hepatitis B virus infections.
BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, specializing in the development of specific and selective antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create novel monoclonal antibody and cell-based therapeutics. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate aimed at treating soft tissue and bone sarcoma, non-small cell lung cancer, and other tumors. BioAtla's pipeline also includes BA3021, targeting non-small cell lung cancer and melanoma, and BA3071, which addresses various cancers such as renal cell carcinoma and bladder cancer. The company's innovative approach enhances drug selectivity for cancer tissues, potentially improving safety and expanding treatment options for previously untreatable cancers. BioAtla holds over 150 issued patents and patent applications, underscoring its commitment to developing safer and more effective cancer therapies.
Obsidian Therapeutics develops innovative cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Founded in 2015 and based in Cambridge, Massachusetts, the company focuses on creating next-generation therapies that utilize pharmacologic operating systems to provide precise control over protein activity within cells. This technology allows for the development of adoptive cell therapies with advanced functionalities that can be managed by physicians using simple, safe, and orally active medications. By offering improved control over treatment, Obsidian Therapeutics aims to provide better outcomes for patients compared to existing cell therapy options.
Swift Health Systems Inc. is a medical device company based in Irvine, California, that specializes in developing innovative orthodontic solutions. The company's flagship product, INBRACE, is an invisible orthodontic system designed to correct malocclusion by being discreetly positioned behind the teeth. INBRACE employs patented self-guiding technology that utilizes light and continuous forces to gently adjust teeth, minimizing discomfort and reducing the frequency of doctor visits. FDA registered, INBRACE aims to make orthodontic treatment more appealing by addressing common patient concerns and facilitating practice growth for clinicians. The system integrates digital treatment planning, computer modeling, and direct digital manufacturing to offer a scalable and personalized approach to a wide range of orthodontic cases, thereby raising the standard of care in the field.
DiCE Therapeutics, founded in 2013 and based in Menlo Park, California, specializes in developing a platform for the discovery of novel small molecules aimed at targets that have previously been difficult to address in the pharmaceutical sector. The company utilizes innovative technology that extends directed evolution, allowing for the direct translation of DNA-encoded information into organic compounds, thereby streamlining the traditionally labor-intensive processes of medicinal chemistry. This platform not only serves the pharmaceutical industry but also has applications in agriculture and materials sciences. The founding team includes notable figures such as Stanford Professor Pehr Harbury, who developed the core technology, and other experienced professionals from various sectors, contributing to the company's mission of transforming drug discovery and development.
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.
Notal Vision develops home-based monitoring systems for patients with age-related macular degeneration. Founded in 2000, the company operates from offices in Tel Aviv, Israel, and Manassas, Virginia. It offers the ForeseeHome device, which enables patients to detect changes in their vision associated with the condition. This device employs Preferential Hyperacuity Perimetry technology to identify subtle vision alterations. Additionally, Notal Vision provides the Notal OCT Analyzer, an algorithm that automates the detection of pathological fluid in exudative retinal diseases, and utilizes optical coherence tomography for noninvasive imaging. The company's platform incorporates AI algorithms to enhance diagnostic decision-making and facilitate patient-activated treatment options. By extending eye disease management from clinical settings to home environments, Notal Vision aims to improve visual outcomes and enable early intervention by eye care professionals.
GenapSys, Inc. develops innovative DNA sequencing technologies for applied genomic testing and medical sequencing. The company's primary product, the GenapSys Sequencer, utilizes electrical-based detection for single nucleotide incorporations, facilitating sequencing in various laboratory settings and automating clonal amplification. GenapSys offers solutions for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. Additionally, the company seeks to collaborate with local health agencies and researchers to enhance access to sequencing insights, particularly for controlling and mitigating outbreaks. The compact and portable nature of the sequencer allows it to operate from standard power sources, making it suitable for deployment in hospitals, airports, and public transportation hubs to provide rapid results for virus samples. Founded in 2010, GenapSys is headquartered in Redwood City, California.
Twinstrand Therapeutics is a biopharmaceutical company that engages in the discovery, development, and commercialization of biological drugs for the treatment of life-threatening diseases. The product of the company is TST10088. It is a recombinant protein-based prodrug for activation by matrix metalloproteinases associated with solid tumor forms of cancer. Twinstrand is a Canada-based company that was founded in 1995. The company was acquired by Cangene on July 7, 2009.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services, which focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides morphologic analysis which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. has a strategic collaboration with Inivata Limited for the commercialization of its InVisionFirst-Lung liquid biopsy test in the United States. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Arcellx is a privately held development-stage company founded in 2015 and located in Montgomery County, Maryland. The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, and responsible patient care. Although our initial clinical focus is cancer therapy, we are committed to extending our Antigen- Receptor Complex T cell (ARC-T) therapies across a broad spectrum of human disease.
Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, founded in 2018. The company focuses on developing innovative therapies for viral diseases, particularly through its oral drug candidate, ATI-2173, aimed at treating patients infected with Hepatitis B and Hepatitis D viruses. With a leadership team that possesses extensive experience in the field, Antios Therapeutics is dedicated to advancing its research and development efforts toward potentially curative treatments for Hepatitis B virus infections.
Field Trip Health, Inc. providing simple, evidence-based therapies for healing and heightening engagement with the world.
In the simplest sense, we’re a company that creates solutions. More specifically, we design novel access device technology for vascular interventions and unmet clinical needs. Because in the precious seconds that surround a stroke emergency, clinicians need technology that delivers. That’s where we come in.
Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. By utilizing its TAm-Seq technology, Inivata enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through a simple blood sample. This non-invasive method, known as liquid biopsy, represents a significant advancement in cancer diagnostics, allowing for improved detection, monitoring, and treatment decision-making. Inivata has also formed a strategic collaboration with NeoGenomics, Inc. to further strengthen its capabilities in this field.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
DiCE Therapeutics, founded in 2013 and based in Menlo Park, California, specializes in developing a platform for the discovery of novel small molecules aimed at targets that have previously been difficult to address in the pharmaceutical sector. The company utilizes innovative technology that extends directed evolution, allowing for the direct translation of DNA-encoded information into organic compounds, thereby streamlining the traditionally labor-intensive processes of medicinal chemistry. This platform not only serves the pharmaceutical industry but also has applications in agriculture and materials sciences. The founding team includes notable figures such as Stanford Professor Pehr Harbury, who developed the core technology, and other experienced professionals from various sectors, contributing to the company's mission of transforming drug discovery and development.
Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer immunotherapies. Founded in 2017, the company is advancing a pipeline of therapeutic candidates designed to stimulate the immune system specifically within the tumor microenvironment. Utilizing its proprietary PREDATOR platform, Werewolf Therapeutics engineers conditionally activated molecules known as INDUKINE, which remain inactive in peripheral tissues but activate selectively in the presence of tumors. This targeted approach aims to enhance both adaptive and innate immune responses, addressing limitations associated with traditional proinflammatory therapies. Through its research and development efforts, Werewolf Therapeutics is committed to transforming cancer treatment.
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions.
SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
Galecto, Inc. is a clinical-stage biotechnology company founded in 2011, focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company leverages over a decade of research on the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic processes. Its therapeutic approach includes small-molecule inhibitors targeting these proteins. Galecto's leading product candidate, GB0139, is aimed at treating severe fibrotic lung diseases, notably idiopathic pulmonary fibrosis, while another candidate, GB1211, is a selective oral galectin-3 inhibitor intended for managing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto is positioned to address critical unmet medical needs in the treatment of fibrotic and related diseases.
Private Equity Round in 2020
NeuroPace, Inc. specializes in the design, development, manufacturing, and marketing of implantable devices aimed at treating neurological disorders through responsive stimulation. The company's flagship product, the RNS System, is specifically designed for patients with medically refractory partial epilepsy. This system includes a small implantable neurostimulator that monitors brain activity and delivers electrical pulses to targeted areas to prevent seizures. The RNS System comprises various components, such as depth leads and cortical strip leads for implantation, along with external devices like a programmer that allows healthcare professionals to communicate with the neurostimulator. Founded in 1997, NeuroPace is headquartered in Mountain View, California.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Mission Bio, Inc. specializes in tools for studying cellular heterogeneity in human health and life science research. The company utilizes microfluidic droplet technology to provide solutions for molecular analysis at the single-cell level. Its flagship product, the Tapestri Platform, is the first single-cell multi-omics platform, allowing for the simultaneous detection of genotype and phenotype from the same cell, which enhances the understanding of disease progression and treatment responses. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating targeted single-cell DNA custom panels, applicable in various fields including oncology, blood cancers, solid tumors, and genome editing validation. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.
Verona Pharma is a clinical-stage biopharmaceutical company headquartered in London, United Kingdom, that specializes in developing therapies for chronic respiratory diseases with significant unmet medical needs. The company's lead product candidate, ensifentrine, is an inhaled dual inhibitor of phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), and alternative delivery methods, including a dry powder inhaler and a pressurized metered-dose inhaler, are also being explored. In addition to COPD, Verona Pharma aims to develop ensifentrine for other respiratory conditions such as cystic fibrosis and asthma. Founded in 2005, the company is committed to improving the health and quality of life for individuals affected by these challenging diseases.
BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, specializing in the development of specific and selective antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create novel monoclonal antibody and cell-based therapeutics. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate aimed at treating soft tissue and bone sarcoma, non-small cell lung cancer, and other tumors. BioAtla's pipeline also includes BA3021, targeting non-small cell lung cancer and melanoma, and BA3071, which addresses various cancers such as renal cell carcinoma and bladder cancer. The company's innovative approach enhances drug selectivity for cancer tissues, potentially improving safety and expanding treatment options for previously untreatable cancers. BioAtla holds over 150 issued patents and patent applications, underscoring its commitment to developing safer and more effective cancer therapies.
COMPASS Pathways is a mental health care company focused on developing innovative treatments for mental health conditions. It specializes in the formulation of COMP360, a psilocybin-based therapy currently undergoing Phase IIb clinical trials aimed at treating patients with treatment-resistant depression. The company operates across multiple sites in Europe and North America, conducting large-scale clinical trials to evaluate the efficacy and safety of its psilocybin therapy. Founded in 2016 and incorporated in 2020, COMPASS Pathways is headquartered in Altrincham, Cheshire, United Kingdom. The company's mission is to enhance patient access to evidence-based mental health solutions.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.
ArcherDX, Inc. is a genomics company based in Boulder, Colorado, focused on advancing molecular pathology through next-generation sequencing technology. Established in 2013, the company develops and commercializes a range of research products, including DNA-based VariantPlex, RNA-based FusionPlex, ctDNA-based LiquidPlex, and RNA-based Immunoverse, aimed at optimizing therapy and monitoring cancer. ArcherDX also creates in-vitro diagnostic products and offers customizable assay design services to clinical and biopharmaceutical clients, enabling the development of new applications tailored to specific biomarker targets. The Archer platform utilizes proprietary Anchored Multiplexed PCR (AMP™) chemistry and sophisticated bioinformatics to enhance genetic mutation detection significantly. The company's products and services are utilized by academic and reference laboratories, biopharmaceutical firms, and contract research organizations, with ongoing efforts to gain regulatory approval for various companion diagnostic assays. As of October 2020, ArcherDX operates as a subsidiary of Invitae Corporation.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Beta Bionics is a biotechnology company based in Boston, Massachusetts, focused on advancing diabetes care through its innovative bionic pancreas system, known as the iLet. Founded in 2015, the company has developed a dual-chamber infusion pump that precisely delivers insulin and glucagon, allowing for autonomous management of blood sugar levels. The iLet has received breakthrough designation for its various configurations, including insulin-only, glucagon-only, and bihormonal uses, particularly in conjunction with Zealand Pharma’s dasiglucagon, a stable glucagon analog in a ready-to-use solution. By reducing the burden and cost associated with diabetes management, Beta Bionics aims to improve the quality of life for individuals living with diabetes.
Orchestra BioMed, Inc. is a biomedical innovation company established in 2017 and located in New Hope, Pennsylvania. The company is dedicated to developing high-impact therapeutic solutions for medical procedures, with a primary focus on addressing cardiovascular diseases, which account for a significant number of global fatalities annually. Orchestra BioMed aims to accelerate the commercialization of its products through strategic partnerships with medical device companies. Its leading product candidates include BackBeat Cardiac Neuromodulation Therapy, designed for hypertension treatment, and Virtue Sirolimus AngioInfusion Balloon, which targets atherosclerotic artery disease. By emphasizing evidence-based solutions, Orchestra BioMed seeks to improve patient outcomes for serious medical conditions.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.